The advent of haploidentical transplants has led to a decline in cord blood (CB) transplants, especially considering the cost of double-cord transplants. Cord blood expansion techniques, while promising, are likely to be expensive. In this session, a speaker will describe the advantages of combined haplo-unmanipulated CB transplants, including the recent cure of both HIV and myeloid malignancy with this method, and adoptive immunotherapy with unmanipulated CB following chemotherapy for refractory myeloid malignancy. Another speaker will describe the utility of pluripotent stem cells derived from CB in comparison to other starting material sources. They will also review the clinical success with CB-derived immune effector cells such as NK cells and T-regulatory cells.
All relevant financial relationships have been mitigated.
Describe the limitations and advantages of combined haplo-unmanipulated cord blood transplants.
Discuss adoptive immunotherapy with unmanipulated CB units for refractory myeloid malignancy.
Review the utility of CB-derived pluripotent stem cells as well as CB-derived immune effector cells.